CPC-410
CPC-410 is for the treatment of advanced metastatic ADT-resistant and Chemotherapy-resistant PCa.
Loading menu...
| Prostate cancer is the second leading cause of cancer deaths among US men | Over 200,000 new patients are diagnosed with prostate cancer every year in the US alone | About 35,000 of these men have advanced metatstatic prostate tumor for whom there is no cure |
